Research Background

MET amplification drives a key signaling pathway that promotes tumor growth and metastasis in a subset of solid cancers. Current standard therapies rely on chemotherapy or non-specific targeted agents, which have limitations in efficacy and tolerability. Consequently, a novel approach that directly inhibits MET is expected to improve patient survival.

Clinical Design

The Phase 2 trial launched in December 2025 and is currently enrolling approximately 100 patients aged 12 years and older with MET-amplified solid tumors across 50 sites worldwide. Participants receive Telisotumab Adjutecan by intravenous infusion in a single‑arm design, with safety and disease activity monitored over a 61.5‑month period. The protocol is intended to capture early safety and efficacy signals rapidly.

Differentiation Points

Telisotumab Adjutecan is a MET‑targeted antibody‑drug conjugate (ADC) designed to deliver cytotoxic payload selectively to tumor cells, thereby minimizing off‑target toxicity. Although the therapeutic burden may be greater than conventional chemotherapy, precise target delivery is expected to yield durable efficacy and improved tolerability.

Market and Impact

If safety and efficacy outcomes are favorable, the program could become a valuable addition to AbbVie’s oncology portfolio and reshape the competitive landscape of MET‑targeted therapeutics. Companies that have relied on non‑specific treatments may shift focus toward differentiated target‑driven drug development. Investors and partners should monitor the clinical data stream closely.